New partnership for the commercialization of Nucynta® in the U.S. territory

Aachen (ots) - The Grünenthal Group announced today that Nucynta®
(tapentadol) will be commercialized in the U.S. territory by
Collegium Pharmaceutical, Inc., instead of Depomed, Inc., from 2018
onwards.

In recent months, Depomed has been struggling to grow Nucynta®.
Depomed executes its strategy to transform into a specialty
pharmaceutical company with less focus on opioids. Grünenthal has
looked at various options to reinforce the performance of Nucynta®,
and strengthen its presence in the US. But given the dynamics in the
opioid market, Grünenthal concluded and agreed that transferring
Nucynta® to Collegium would be the best option. This agreement should
give Grünenthal a more committed partner and provides a pre-agreed
fixed minimum royalty income stream over the next few years, if the
partner performs within a given range of revenue achievements.

Collegium is focused on pain management developing and
commercializing next generation, abuse-deterrent products for the
treatment of patients suffering from chronic pain and other diseases.
"They are well positioned in the market and successfully increased
the sales of their opioid Xtampza® in a very challenging and
declining US-opioid market", Gabriel Baertschi, CEO Grünenthal Group
said. Nucynta® is highly synergetic for Collegium. It is a perfect
fit to more effectively compete on the market, and meet the needs of
patients, physicians and payors. "We believe that adding Nucynta® to
their portfolio will expand the continuum of care for pain patients
and strengthen Collegium as a leader in pain management", Gabriel
Baertschi stated.

Collegium is strongly incentivized to make Nucynta® a success by
paying a fixed royalty even for sales below a certain level (between
$ 180 mn and $ 243 mn), and being rewarded if they exceed the upper
range of the forecast ($ 258 mn). Grünenthal will continue to receive
a royalty rate based on certain net sales thresholds and will receive
a fixed royalty income in the first four years, if the sales are
above $ 180 mn. This agreement contributes to Grünenthal's financial
strength and to some extent removes the uncertainties linked to the
US-market development, while providing Grünenthal with a partner
committed to pain management in the U.S.

About Grünenthal

The Grünenthal Group is an entrepreneurial, science-based
pharmaceutical company specialized in pain, gout and inflammation.
Our ambition is to deliver four to five new products to patients in
diseases with high unmet medical need by 2022 and become a EUR 2 bn
company. We are a fully integrated research & development company
with a long track record of bringing innovative pain treatments and
state-of-the-art technologies to patients. By sustainably investing
in our R&D above the industrial average, we are strongly committed to
innovation.

Grünenthal is an independent, family-owned company headquartered
in Aachen, Germany. We are present in 32 countries with affiliates in
Europe, Latin America and the US. Our products are sold in more than
155 countries and approx. 5,500 employees are working for the
Grünenthal Group worldwide. In 2016, Grünenthal achieved revenues of
approx. EUR 1.4 bn.

More information www.grunenthal.com Follow us on LinkedIn
"Grunenthal Group".

Contact:
Steffen Fritzsche, Head of Corporate Communications
Tel.: +49 241 569-1335,
Fax.: +49 241 569-51335,
steffen.fritzsche@grunenthal.com

Grünenthal GmbH, 52099 Aachen, Germany, www.grunenthal.com

Original-Content von: Grünenthal Group, übermittelt durch news aktuell